Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ALB | P02768 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | TYMP | P19971 | 5/20 | 0.47 |
| ▸ | TK1 | P04183 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19974371 | 1.00 | ALDH1A1 (0.53) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL19974393 | 1.00 | ALDH1A1 (0.53) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL9293772 | 0.80 | ALDH1A1 (0.52) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL19987163 | 0.80 | SLC28A1 (0.51) | — | |
| SCHEMBL21490243 | 0.80 | SLC28A1 (0.51) | — | |
| SCHEMBL19987242 | 0.80 | SLC28A1 (0.51) | — | |
| SCHEMBL12150907 | 0.78 | ALDH1A1 (0.54) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL30807829 | 0.76 | ALDH1A1 (0.55) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL9487631 | 0.75 | ALDH1A1 (0.44) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL750555 | 0.74 | TK1 (0.49) | ALDH1A1LMNAALBPOLBADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190322693-A1 | NUCLEOSIDE ANALOGUES AND METHODS OF USE THEREOF | LCB PHARMA INC. (CA) | 2019-10-24 | — | — | US | disclosed |
| WO-2018049535-A1 | NUCLEOSIDE ANALOGUES AND METHODS OF USE THEREOF | LCB PHARMA INC. (CA) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322693-A1 | NUCLEOSIDE ANALOGUES AND METHODS OF USE THEREOF | PNP, TYMP, MTAP | ALDH1A1 3452/4885LMNA 282/4885ALB 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.